ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
企業コードSPRY
会社名ARS Pharmaceuticals Inc
上場日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)
従業員数155
証券種類Ordinary Share
決算期末Dec 04
本社所在地11682 El Camino Real, Suite 300
都市SAN DIEGO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号92130
電話番号18587719307
ウェブサイトhttps://ars-pharma.com/
企業コードSPRY
上場日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし